Cardiometabolic-sleep treatment market seen reaching $10.58B by 2030

By AI, Created 5:00 PM UTC, May 18, 2026, /AGP/ – The Business Research Company says the global market for cardiometabolic-sleep comorbidity treatment will grow from $6.25 billion in 2025 to $10.58 billion by 2030. The forecast points to rising sleep-disorder and cardiometabolic disease burdens, plus broader use of AI risk tools, telemonitoring and combination therapies.

Why it matters: - The market targets patients with overlapping sleep disorders and cardiometabolic conditions such as obesity, diabetes, hypertension and cardiovascular disease. - Treating both conditions together can improve sleep quality, metabolic health and long-term outcomes. - The growth outlook signals more demand for integrated care, devices, medications and patient monitoring services.

What happened: - The Business Research Company released its “Cardiometabolic-Sleep Comorbidity Treatment Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035.” - The report estimates the market will rise from $6.25 billion in 2025 to $6.94 billion in 2026. - The report projects the market will reach $10.58 billion by 2030. - The forecast implies a 10.9% CAGR from 2025 to 2026 and 11.1% CAGR through 2030. - The company published the release in London on May 14, 2026. - A free sample is available here.

The details: - Historical growth has been driven by rising obstructive sleep apnea and obesity, higher awareness of cardiometabolic disorders, wider use of positive airway pressure devices, more hospital and sleep clinic infrastructure and a stronger focus on lifestyle intervention. - Future growth is expected to come from AI-based risk scoring and predictive analytics, broader telemonitoring adoption, combination pharmacotherapies, personalized care management services and patient education and adherence programs. - In 2025, North America was the largest regional market. - Asia-Pacific is forecast to be the fastest-growing region during the projection period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The full report is available here.

Between the lines: - The forecast reflects a broader shift toward managing sleep and metabolic disease as linked clinical problems rather than separate ones. - The emphasis on AI, telemonitoring and adherence programs suggests the market is moving beyond one-time treatment toward ongoing digital and personalized care. - The CDC data cited in the release underscores the scale of the underlying disease burden: cardiovascular disease caused 919,032 deaths in the U.S. in 2023, or roughly one in every three deaths. - Coronary heart disease was the most common form, accounting for nearly one in six deaths among adults under 65.

What’s next: - The market’s next phase likely depends on whether health systems expand integrated treatment pathways and remote monitoring. - North America is set to remain the largest market unless faster adoption in Asia-Pacific narrows the gap. - The company is steering readers toward related reports on genomic urine testing, ocular genetic diagnostic and live attenuated polio vaccine markets.

The bottom line: - Cardiometabolic-sleep comorbidity treatment is emerging as a growing niche at the intersection of chronic disease, sleep medicine and digital care.